Demonstration Formulary
1 Gastro-intestinal system
fgsdfgsdfgs
01-05-01 Aminosalicylates
Amber Recommended -Sandwell only
Green -Walsall only
Amber Specialist Initiation continued in Primary Care -Wolverhampton only
Amber SC-Dudley only
| Sulfasalazine |
|
Formulary
|
Plain tablets are more cost effective than enteric coated tablets Walsall
Sandwell
Wolverhampton
ESCA Sulfasalazine-Wolverhampton only Dudley
|
 Potential Primary Care Medication Error: Confusing sulfasalazine and sulfadiazine (The Royal Wolverhampton NHS Trust, 17/03/2021) |
|
Links
NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)- NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
- NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
- Potential Primary Care Medication Error: Confusing sulfasalazine and sulfadiazine (The Royal Wolverhampton NHS Trust, 17/03/2021)
- UKMI Q&A: Mesalazine - Differences between oral preparations -